Stacks Image 2253

New filtration technologies for antibody removal from donated blood components

New filtration technologies for antibody removal from donated blood components

The Problem

Blood components from donated blood contain potentially harmful antibodies, which can cause serious adverse reactions to blood transfusion. Such reactions can be initiated by blood group specific antibodies reacting with patients' red cells when plasma-rich components are transfused to patients of different ABO groups. The ability to effectively remove specific antibodies by means of a filter would positively impact the safety of the recipient of the blood component, as well as reduce the logistical complexities within Health Services (such as the NHS) by simplifying inventory and enabling the easy supply of antibody-free blood components to patients.

The Sanguis project was founded to tackle these issues.

Blood components from donated blood contain potentially harmful antibodies, which can cause serious adverse reactions to blood transfusion. Such reactions can be initiated by blood group specific antibodies reacting with patients' red cells when plasma-rich components are transfused to patients of different ABO groups. The ability to effectively remove specific antibodies by means of a filter would positively impact the safety of the recipient of the blood component, as well as reduce the logistical complexities within Health Services (such as the NHS) by simplifying inventory and enabling the easy supply of antibody-free blood components to patients.

The Sanguis project was founded to tackle these issues.

The Project

The Sanguis project was founded to develop a new filtration technology to remove antibodies from donated blood components. This business-driven, collaborative project is led by the Nonwovens Innovation & Research Institute Ltd (NIRI), and draws on the expertise of the four partner organisations, each providing unique knowledge and input to the project. The other partners are chemistry specialists Carbosynth Ltd., leading blood filter manufacturer Macopharma, and NHS Blood and Transplant (NHSBT), which provides invaluable input on end user needs.

The Sanguis project was founded to develop a new filtration technology to remove antibodies from donated blood components. This business-driven, collaborative project is led by the Nonwovens Innovation & Research Institute Ltd (NIRI), and draws on the expertise of the four partner organisations, each providing unique knowledge and input to the project. The other partners are chemistry specialists Carbosynth Ltd., leading blood filter manufacturer Macopharma, and NHS Blood and Transplant (NHSBT), which provides invaluable input on end user needs.

The Technology

Through a combination of groundbreaking textile engineering and advanced chemistry, the Sanguis project has successfully developed the technology to enable antibodies to be filtered from donated blood. The project team is now working to refine and commercialise the technology.

Through a combination of groundbreaking textile engineering and advanced chemistry, the Sanguis project has successfully developed the technology to enable antibodies to be filtered from donated blood. The project team is now working to refine and commercialise the technology.

The Team

Click a logo to learn more about the members of the Sanguis development team.

Click a logo to learn more about the members of the Sanguis development team.

  • Stacks Image 2354
  • Stacks Image 2359
  • Stacks Image 2365
  • Stacks Image 2357

Innovate UK

The Sanguis project would not have been possible without the support of Innovate UK. The consortium was awarded grant funding by Innovate UK, following an open competition.

Innovate UK is an executive body established by the UK Government to drive innovation. It promotes and invests in research, development and the exploitation of science, technology and new ideas for the benefit of business - increasing sustainable economic growth in the UK and improving quality of life.

The Sanguis project would not have been possible without the support of Innovate UK. The consortium was awarded grant funding by Innovate UK, following an open competition.

Innovate UK is an executive body established by the UK Government to drive innovation. It promotes and invests in research, development and the exploitation of science, technology and new ideas for the benefit of business - increasing sustainable economic growth in the UK and improving quality of life.

Contact Us

Ross Ward
NIRI Ltd.
169 Meanwood Road
Leeds
LS7 1SR
United Kingdom
0113 350 3829
rossw@nonwovens-innovation.com

Ross Ward
NIRI Ltd.
169 Meanwood Road
Leeds
LS7 1SR
United Kingdom

0113 350 3829

rossw@nonwovens-innovation.com